Agriculture is cautiously entering a new era in which raw planting data holds both the promise of higher yields and the peril that the information could be hacked or exploited by corporations or government agencies.
Medicaid and Medicare fraud is where the real money lies, costing taxpayers some $100 billion a year, or 10 percent of total costs. This is many times more than the highest estimate of fraud in all other assistance programs combined. Nearly all of this fraud is perpetrated by health care providers.
Indianapolis is striving to become an electric-vehicles center. Gas tax revenue is declining, though, as people drive less and as more fuel-efficient new cars require filling up less at the pump. That saves people money, reduces pollution and lessens America’s imports of foreign oil.
Minneapolis-based 3M spent nearly $16 million in 2008 on local buildings and equipment for Aearo Technologies, but hasn’t hit hiring targets set out in a seven-year tax-abatement agreement.
More than five years after U.S. governors began a bipartisan effort to set new standards in American schools, the Common Core initiative has morphed into a political tempest fueling division among Republicans.
The latest Indiana General Assembly, which wrapped up a “short” session March 14, tackled a rather lengthy list of bills. We look at how some notable proposals fared.
I don’t know Jim Irsay personally, but I feel like I know him. I’d like to know him better. I’ve been thinking a lot about Jim and his situation the last few days. I keep wondering if there’s something I can do to help, and for now this column is my best effort in that regard.
Indianapolis Business Journal gathered tech leaders for a Technology Power Breakfast panel discussion March 14. The panel talked about topics ranging from ExactTarget to mentors to raising capital.
For 2014, at least, Obamacare's dreams of expanding individual insurance coverage in Indiana have simply failed. There's no getting around it.
Disagreements about education reform result from conflicting models: the business model and the social model. Governors such as Daniels and Pence, reflecting their backgrounds and support structures, tend toward the business model. Superintendent Ritz, with almost 35 years as a teacher/communications coordinator in elementary schools, is more aligned with the social model.
Oy. By the time the Bushes and Clintons are finished, they are going to make the Tudors and the Plantagenets look like pikers. Barack Obama will turn out to be the interim guy who provided a tepid respite while Hillary and Jeb geared up to go at it.
Dow AgroSciences LLC is spending millions of dollars and racking up hundreds of patents as its expands ever deeper in the burgeoning global market for genetically modified crops and pesticides.
You’ll see the intrusions clearly in the kind of car you drive and how much you pay for power.
The Republican-controlled U.S. House moved Thursday to block President Barack Obama's plan to limit carbon emissions from new power plants, an election-year strike at the White House aimed at portraying Obama as a job killer.
One of Eli Lilly and Co.’s experimental diabetes drugs was as effective at lowering blood sugar levels as Victoza, the leading drug on the market. Indianapolis-based Lilly said its drug dulaglutide showed “non-inferiority” when tested against the strongest dose of Victoza, a best-selling drug for Type 2 diabetics made by Denmark-based Novo Nordisk A/S. The study of 599 patients examined the effect on hemoglobin A1c scores, a measure of diabetes control. Lilly said it would wait to disclose detailed results of its Phase 3 clinical trial of the two drugs until scientific meetings later this year. But the result is good news for Lilly, which is counting on dulaglutide and a few other drugs it plans to launch this year to rejuvenate its sales after the patent expiration in December of its top-selling drug, Cymbalta. Before the latest study, Wall Street analysts predicted dulaglutide could achieve $1.5 billion a year in sales. Victoza generated $2.1 billion in 2013 sales for Novo Nordisk, according to data compiled by Bloomberg, and was the top seller in its class. Dulaglutide has already proved itself superior to other diabetes drugs, including metformin, Byetta and Januvia, in clinicial studies announced last year. Dulaglutide has been submitted to U.S. regulators for approval, with a decision expected by September.
Pharmacists would be able to substitute an interchangeable biosimilar drug for a prescribed name-brand product under a bill passed by the Indiana House of Representatives last week. The bill now moves to the Governor’s Office for consideration. The legislation, authored by Sen. Brandt Hershman, R-Buck Creek, creates a series of steps to ensure the safety of automatic substitution of biosimilar medications. Senate Bill 262 includes five principles supported by BIO, the Biotechnology Industry Organization. Biosimilar drugs are generic versions of biotech drugs, which are developed from organically produced proteins. Traditional pills are synthesized from chemicals.
Louisville-based KentuckyOne Health, a hospital system that employs more than 14,000 people in Kentucky and southern Indiana, has laid off about 500 people to help reduce a $218 million deficit, according to the Associated Press. In addition, the company said it would not fill 200 job vacancies, to further reduce costs. Hospital systems across the country have begun slashing work forces to reduce bloated budgets after years of aggressive building, while adjusting to lower Medicare reimbursement and reductions in Medicaid funding.
Even though the state’s three largest hospital systems–IU Health, St. Vincent Health and Franciscan Alliance–eliminated a combined 2,700 jobs, it created just a blip in the long-term run-up in hospital employment.
